1290539-90-0

Upstream product

• 207405-61-6 5-oximino-2-azabicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester 
• 198835-06-2 5-oxo-2-azabicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 542-92-7 cyclopenta-1,3-diene 
• 1400808-00-5 5-oxo-2-azabicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester 
• 207405-64-9 tert-butyl (1R,4R)-5-(benzylamino)-2-azabicyclo[2.2.1]heptane-2-carboxylate 
• 207405-64-9 C₁₈H₂₆N₂O₂ 
• 207405-64-9 (1R,4R,5R)-tert-butyl 5-(benzylamino)-2-azabicyclo[2.2.1]heptanes-2-carboxylate 
• 702666-73-7 tert-butyl (1R,4S)-(+)-2-azabicyclo[2.2.1]hept-5-ene-2-carboxylate 
• 207405-69-4 (1R,4R,5S)-tert-butyl 5-hydroxy-2-azabicyclo[2.2.1]heptanes-2-carboxylate 
• 79200-56-9 (-)-2-azabicyclo[2.2.1]hept-5-en-3-one 
• 207405-64-9 tert-butyl 5-(benzylamino)-2-azabicyclo[2.2.1]heptane-2-carboxylate 
• 198835-06-2 tert-butyl 5-oxo-2-azabicyclo[2.2.1]heptane-2-carboxylate 
• 49805-30-3 2-azabicyclo[2.2.1.]hept-5-en-3-one 

Relevant academic research and scientific papers

NOVEL QUINOLINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE

The present invention relates to compounds of formula (I), (I), wherein R1, R2 and R3 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

Nitrogen-containing heterocyclic derivative and preparation thereof

The invention discloses a nitrogen-containing heterocyclic compound as shown in a formula (I), a stereoisomer, a solvate, a metabolite, a pharmaceutically acceptable salt, a co-crystal or a prodrug of the nitrogen-containing heterocyclic compound, a pharmaceutical composition of the nitrogen-containing heterocyclic compound, a preparation method of the nitrogen-containing heterocyclic compound, and an application of the nitrogen-containing heterocyclic compound in prevention and treatment of autotaxin mediated diseases.

NITROGEN HETEROCYCLIC COMPOUNDS AND METHODS OF USE

The present disclosure relates to compounds of formula (I): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparing the compounds, compositions comprising the compounds, and methods of using the compounds as inhibitors of receptor tyrosine kinases, in particular oncogenic mutants of ErbB-receptors e.g. in the treatment of cancer.

Synthesis and biological evaluation of pyrimidine derivatives with diverse azabicyclic ether/amine as novel GPR119 agonist

A class of novel pyrimidine derivatives bearing diverse conformationally restricted azabicyclic ether/amine were designed, synthesized and evaluated for their GPR119 agonist activities against type 2 diabetes. Most compounds exhibited superior hEC50

TRICYCLIC GYRASE INHIBITORS FOR USE AS ANTIBACTERIAL AGENTS

Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. In addition, species of tricyclic gyrase inhibitors compounds are also disclosed herein. Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.

TRICYCLIC GYRASE INHIBITORS

Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.

BRIDGED BICYCLIC RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE

The present invention is directed to synthetic bridged bicyclic compounds that are inhibitors of rho-associated protein kinase. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptab

Improved synthesis of monoprotected 5- and 6-amino-2-azanorbornanes

(Chemical Equation Presented) An improved synthesis of Boc-monoprotected 5- and 6-amino-2-azanorbornanes is reported. The synthetic scheme consists of five steps and allows multigram quantities of the title compounds to be obtained. The regio- and stereochemistries of the products are established by two-dimensional NMR experiments. Copyright Taylor & Francis Group, LLC.

PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS

The invention relates to compounds of formula (I) wherein Z, Rc, y, m, u, Ar2, n, X, Rc', l and Ar2 are as described herein. These compounds are neurokinin antagonists. These compounds are useful in the treatment of chronic airway diseases such as asthma.